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Abstract
Activation of the P2Y1 nucleotide receptor in platelets by ADP causes changes in shape and
aggregation, mediated by activation of phospholipase C (PLC). Recently, MRS2500 (2-iodo-N6-
methyl-(N)-methanocarba-2′-deoxyadenosine-3′,5′-bisphosphate) was introduced as a highly
potent and selective antagonist for this receptor. We have studied the actions of MRS2500 in
human platelets and compared these effects with the effects of two acyclic nucleotide analogues, a
bisphosphate MRS2298 and a bisphosphonate derivative MRS2496, which act as P2Y1 receptor
antagonists, although less potently than MRS2500. Improved synthetic methods for MRS2500 and
MRS2496 were devised. The bisphosphonate is predicted to be more stable in general in
biological systems than phosphate antagonists due to the non-hydrolyzable C–P bond. MRS2500
inhibited the ADP-induced aggregation of human platelets with an IC50 value of 0.95 nM.
MRS2298 and MRS2496 also both inhibited the ADP-induced aggregation of human platelets
with IC50 values of 62.8 nM and 1.5 μM, respectively. A similar order of potency was observed
for the three antagonists in binding to the recombinant human P2Y1 receptor and in inhibition of
ADP-induced shape change and ADP-induced rise in intracellular Ca2+. No substantial
antagonism of the pathway linked to the inhibition of cyclic AMP was observed for the nucleotide
derivatives, indicating no interaction of these three P2Y1 receptor antagonists with the
proaggregatory P2Y12 receptor, which is also activated by ADP. Thus, all three of the
bisphosphate derivatives are highly selective antagonists of the platelet P2Y1 receptor, and
MRS2500 is the most potent such antagonist yet reported.
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The P2 receptors for extracellular nucleotides are divided into two structurally-unrelated
superfamilies: the P2Y receptors, which are G protein-coupled receptors (GPCRs), and the
P2X receptors, which are ligand-gated ion channels (LGICs) [1,2]. The P2Y1,2,4,6,11
receptors couple preferentially to the activation of phospholipase C (PLC), via
heterotrimeric G proteins of the Gq family and therefore induce an increase in intracellular
calcium. The P2Y12,13,14 receptors are coupled preferentially to the inhibition of adenylate
cyclase via heterotrimeric G proteins of the Gi family. The P2Y receptors are activated by
adenine and/or uracil nucleotides [3]. The P2Y2 receptor is the only human subtype that is
activated by both ATP and UTP (but not the corresponding 5′-diphosphates). The
pyrimidine-selective receptors include the P2Y4, P2Y6 and P2Y14 receptors, which are
activated by UTP, UDP and UDP-glucose, respectively [4]. The remaining subtypes (P2Y1,
P2Y11, P2Y12 and P2Y13 receptors) are activated by adenine nucleotides.
ADP is released from platelets and endothelial cells to induce aggregation of platelets and
promote intravascular coagulation by acting at the P2Y1 and P2Y12 receptors [5-10].
Antagonists of either P2Y receptor subtype display antiaggregatory properties. A mouse line
lacking expression of the P2Y1 receptor has been constructed [11,12], and the absence of
P2Y1 receptors in platelets of these mice interfered with ADP-promoted aggregation and in
vivo thrombus formation. A third nucleotide receptor, the P2X1 receptor, is present on
platelets, and its role in aggregation appears to be most evident under conditions of high
shear stress [13,31].
Fig. 1 illustrates the chemical structures of a variety of recently-introduced antagonists of
the P2Y1 receptor. The structures differ markedly in the nature of the ribose-like moiety to
which the adenine nucleobase is attached. MRS2179 (N6-methyl-2′-deoxyadenosine 3′,5′-
bisphosphate) 1 and its 2-chloro analogue MRS2216 2 (Fig. 1) have been designed as
nucleotide antagonists of the P2Y1 receptor [14-19]. In suspensions of washed human
platelets, MRS2179 inhibited ADP-induced platelet shape change, aggregation and Ca2+ rise
but had no effect on ADP-induced inhibition of adenylate cyclase [20]. Binding studies
using 33P-labeled MRS2179 demonstrated the presence of an average of 134 binding sites
per platelet. MRS2179 inhibited both arterial and venous thrombosis, further establishing
this receptor as a potential target for antithrombotic drugs [21]. Further structural
modification resulted in the highly potent P2Y1 receptor antagonists MRS2279 3 and the 2-
iodo analogue MRS2500 4 [19], containing the rigid (N)-methanocarba ring system.
MRS2279 has been radiolabeled for use as a high affinity, competitive radiotracer in binding
experiments [18], We previously characterized the SAR (structure activity relationship) as
P2Y1 receptor antagonists of acyclic analogues of adenine nucleotides, containing two
phosphate groups on a symmetrically-branched aliphatic chain, attached at the 9-position of
adenine [22,23]. The submicromolar potency of the acyclic P2Y1 receptor antagonists
MRS2298 5 and MRS2496 6, both related to a 2-chloro-N6-methyladenine-9-(2-
methylpropyl) scaffold, indicated that the ribose ring structure itself is not necessary for
receptor recognition but rather serves as a spacer. A significant correlation was observed
between the capacity of several of these P2Y1 receptor antagonists to inhibit ADP-induced
platelet aggregation in rat platelets [5,23] and the inhibition of P2Y1 receptor-stimulated
phospholipase C activity previously determined in turkey erythrocytes [22]. The present
study compares the activity of three of these P2Y1 receptor antagonists on aggregatory
properties and second messenger (cAMP and PLC) signaling in human platelets.
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2. Materials and methods
2.1. Reagents
myo-[3H]Inositol (20 Ci/mmol) was obtained from American Radiolabeled Chemicals.
Dowex AG 1-X8 resin was purchased from Bio-Rad. DMEM and FBS were from Life
Technologies. All other reagents were purchased from Sigma–Aldrich Chemical Co. HPLC
mobile phases consisted of System A: linear gradient solvent system: CH3CN/triethyl
ammonium acetate from 5/95 to 60/40 in 20 min, flow rate 1.0 mL/min; System B: linear
gradient solvent system: CH3CN/tetrabutyl ammonium phosphate from 20/80 to 60/40 in 20
min, flow rate 1.0 mL/min. Apyrase was a kind gift of R.L. Kinlough-Rathbone (McMaster
University, Hamilton, Ontario): the activity of the compound was such that the enzyme (1
μL/mL) converted 0.25 μmol/L ATP to adenosine monophosphate within 120 s at 37 °C.
2.2. Chemical synthesis
The following synthetic methods are depicted schematically in Fig. 2.
2.2.1. (1′R,2′S,4′R,5′S)-4-(tert-Butyl-diphenyl-silanyloxy)-1-hydroxymethyl-
bicyclo[3.1.0]hexan-2-ol (8)—To a solution of acetic acid 1-acetoxymethyl-4-hydroxy-
bicyclo [3.1.0]hex-2-yl ester 7 ([24], 750 mg, 3.29 mmol) in CH2C12 (10 mL) was added 4-
N,N-dimethylaminopyridine (50 mg, 0.41 mmol), Triethylamine (1.00 mL, 7.17 mmol) and
t-butyl-diphenylsilyl chloride (TBDPS, 1.85 mL, 7.11 mol) and the reaction mixture was
stirred at rt for 23 h. The reaction mixture was diluted with ethyl acetate (EtOAc) and was
washed sequentially with 5% citric acid, brine, sat NaHCO3, and brine. The organic layer
was dried over Na2SO4 and the solvent evaporated. The residue was dissolved in MeOH (50
mL) and K2CO3 (166 mg, 1.20 mmol) was added. The reaction mixture was stirred at rt for
3 days and evaporated. The residue was dissolved with AcOEt and washed with 5% citric
acid, sat NaHCO3, and brine, and dried over Na2SO4 and the solvent evaporated. The
residue obtained was purified by column chromatography (silica gel, eluent: AcOEt/
petroleum ether = 1/2 then 1/0), to give 8 (1.24 g, 99%). 1H NMR (CDCl3) δ 7.72–7.62 (m,
4H), 7.43–7.34 (m, 6H), 4.36–4.23 (m, 2H), 3.72 (dd, 1H, J = 5.1, 11.1 Hz), 3.50 (dd, 1H, J
= 5.7, 11.1 Hz), 2.17–2.06 (m, 1H), 1.83 (d, 1H, J = 5.1 Hz), 1.57 (m, 1H), 1.32 (m, 2H),
1.04 (s, 9H), 0.55 (t, 1H, J = 7.7 Hz); MS (m/e) (positive-FAB) 381 (M − H)+, 405 (M +
Na)+.
2.2.2. (1′R,2′S,4′R,5′S)-Phosphoric acid di-tert-butyl ester 4-(tert-butyl-
diphenyl-silanyloxy)-1-(di-tert-butoxy-phosphoryloxymethyl)-
bicyclo[3.1.0]hex-2-yl ester (9)—To a stirred solution of 8 (82 mg, 0.21 mmol) and 1H-
tetrazole (79 mg, 1.13 mmol) in anhydrous tetrahydrofuran (THF, 2.0 mL) was added di-t-
butyl diethylphosphoramidite (0.400 mL, 1.44 mmol), and the reaction mixture was stirred
for 3 h at room temperature. The reaction mixture was cooled to −78 °C and treated with a
solution of m-chloroperbenzoic acid (70% max, 530 mg) in CH2Cl2 (5.0 mL). The resulting
mixture was warmed to room temperature and stirred for 30 min. 5% NaHSO3 (2.0 mL) was
added to the reaction mixture, and was stirred for another 10 min at room temperature. The
reaction mixture was extracted with AcOEt and the organic phase was subsequently washed
with saturated aqueous NaHCO3 and brine and dried over Na2SO4 and filtered. The solvent
was removed under reduced pressure. The obtained residue was purified by silica gel
column chromatography (AcOEt/petroleum ether = 1/2 to 1/0), to give 9 (152 mg, 93%). 1H
NMR (CDC13) δ 7.70–7.60 (m, 4H), 7.43–7.31 (m, 6H), 4.72 (m, 1H), 4.32 (m, 2H), 3.61
(dd, 1H, J = 6.9, 11.4 Hz), 2.27 (dt, 1H, J = 7.5, 13.5 Hz), 1.72 (m, 1H), 1.52 (s, 9H), 1.46
(s, 18H), 1.39 (s, 9H), 1.33 (s, 9H), 1.26 (m, 1H), 1.07(m, 1H), 0.67(m, 1H); MS (m/e)
(positive-FAB) 767 (M + H)+.
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2.2.3. (1′R,2′S,4′R,5′S)-Phosphoric acid di-tert-butyl ester 1-(di-tert-butoxy-
phosphoryloxymethyl)-4-hydroxy-bicyclo[3.1.0]hex-2-yl ester (10)—To a stirred
solution of 9 (2.16 g, 2.81 mmol) in 6.0 mL of anhydrous THF was added 1.0 M tetrabutyl
ammonium fluoride THF solution (4.3 mL, 4.3 mmol) and the reaction mixture was stirred
at room temperature for 24 h. The solvent was removed under reduced pressure. The residue
obtained was purified by silica gel column chromatography (MeOH/CHCl3 = 1/10), which
furnished 10 (1.34 g, 90%). 1H NMR (CDCl3) 4.89 (q, 1H, J = 7.4 Hz), 4.41 (m, 2H), 3.69
(dd, 1H, J = 6.9, 10.8 Hz), 2.46 (dt, 1H, J = 8.0, 13.5 Hz), 1.80 (m, 1H), 1.49 (s, 18H),
1.48(s, 9H), 1.47 (s, 9H), 1.23 (m, 1H), 1.09 (m, 1H), 0.69 (m, 1H); MS (m/e) (positive-
FAB) 529 (M + H)+.
2.2.4. (1′R,2′S,4′S,5′S)-Phosphoric acid di-tert-butyl ester 1-(di-tert-butoxy-
phosphoryloxymethyl)-4-(6-chloro-2-iodo-purin-9-yl)-bicyclo[3.1.0]hex-2-yl
ester (11)—To a solution of triphenylphosphine (101 mg, 0.385 mmol) in anhydrous THF
(1.00 mL) was added diisopropyl azodicarboxylate (0.075 mL, 0.38 mmol) at rt with stirring
for 1.5 h. Compound 10 (102 mg, 0.194 mmol) and 6-chloro-2-iodopurine ([19], 70 mg,
0.25 mmol) in THF (2.20 mL) were added to the reaction mixture, and it was stirred at room
temperature for 23 h. The solvent was removed under vacuum and the residue obtained was
purified by preparative thin-layer chromatography (AcOEt), which furnished 11 (81.3 mg,
53%). 1H-NMR (CDC13) δ 8.44 (s, 1H), 5.34 (dd, 1H, J = 8.1, 15.0 Hz), 5.16 (d, 1H, J = 6.9
Hz), 4.69 (dd, 1H, J = 5.1, 11.4 Hz), 3.94 (dd, 1H, J = 6.6, 11.4 Hz), 2.40–2.30 (m, 1H),
2.22–2.10 (m, 1H), 1.85–1.80 (m, 1H), 1.50 (s, 9H), 1.49 (s, 18H), 1.48 (s, 9H), 1.18–1.14
(m, 1H), 1.09–1.03(m, 1H); MS (m/e) (positive-FAB) 791, 793 (peak height ratio 3:1) (M +
H)+.
2.2.5. (1′R,2′S,4′S,5′S)-4-(6-chloro-2-iodo-9H-purin-9-yl)-1-[(phosphato)-
methyl]-2-(phosphato)-bicyclo[3.1.0]hexane tetrakis ammonium salt (12)—A
mixture of 11 (33.0 mg, 0.042 mmol) in CH2C12 (3 mL) was treated with trifluoroacetic
acid (TFA, 0.100 mL) and the reaction mixture was stirred at room temperature for 3 h.
After removal of the solvent, the crude 12 was purified with ion-exchange column
chromatography with the use of Sephadex-DEAE-A-25 resin with a linear gradient (0.01–
0.7 M) of 0.5 M NH4HCO3 as the mobile phase. After lyophilization, 12 (16.3 mg, 62%)
was obtained as a white solid. 1H NMR(D2O) δ 8.83 (s, 1H), 5.30–5.20 (m, 1H), 5.16 (d,
1H, J = 6.3 Hz), 4.60–4.50 (m, 1H), 3.75–3.65 (m, 1H), 2.40–2.20 (m, 1H), 2.10–1.95 (m,
1H), 1.95–1.90 (m, 1H), 1.25–1.20 (m, 1H), 1.05–1.00 (m, 1H); 31P NMR (D2O) δ 2.02,
1.40 (2s, 3′-P, 5′-P); MS (m/e) (negative-FAB) 565, 567 (peak height ratio = 3:1) (M − H)+;
HPLC 9.8 min (98%) in solvent system A, 16.0 min (98%) in solvent system B.
2.2.6. (1′R,2′S,4′S,5′S)-4-(2-iodo-6-methylamino-purin-9-yl)-l-[(phosphato)-
methyl]-2-(phosphato)-bicyclo[3.1.0]hexane (4)—To a solution of 12 (10.9 mg,
0.017 mmol) in water (5.00 mL) was added 40% MeNH2 in water (1.0 mL) and the reaction
mixture was stirred for 2 h at room temperature. The reaction was monitored by HPLC. The
reaction mixture was subsequently frozen and lyophilized. Purification of the residue
obtained was performed on an ion-exchange column packed with Sephadex-DEAE A-25
resin. A linear gradient (0.01–0.7 M) of 0.5 M ammonium bicarbonate was applied as the
mobile phase, and UV and HPLC were used to monitor the elution, which furnished 4 (10.2
mg, 95%). 1H NMR (D2O) δ 8.54 (bs, 1H), 5.19 (m, 1H), 5.01 (d, 1H, J = 6.9 Hz), 4.58 (dd,
1H, J = 4.7, 11.3 Hz), 3.73 (dd, 1H, J = 4.4, 11.0 Hz), 3.07 (bs, 3H), 2.28 (dd, 1H, J = 7.7,
14.6 Hz), 1.92–2.09 (m, 2H), 1.26 (dd, 1H, J = 4.1, 6.1 Hz), 1.06 (dd, 1H, J = 9.7, 16.3
Hz). 31P NMR (D2O) 0.651 (s). High-resolution MS (negative-ion FAB) calcd for
C13H17N5O8P2I 559.9597, found 559.9604, HPLC 9.8 min (99%) in solvent system A, 15.4
min (99%) in system B.
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2.2.7. Tetraethyl 2-hydroxymethyl-1,3-propanebisphosphonate (14)—Compound
13 (3.28 g, 10 mmol) was dissolved in THF (25 mL) and BH3-THF complex (34 mL of 1 M
in THF, 34 mmol) was added at 0–5 °C, and the reaction mixture was allowed to warm to
room temperature. After stirring for an additional 8 h, the mixture was cooled to 0 °C and
treated with solid K2CO3 (10 g) and 30% hydrogen peroxide (20 mL), added slowly. The
resulting reaction mixture was stirred at room temperature for 2 h. It was then extracted
twice with EtOAc (100 mL × 2), and the combined organic layer was dried over sodium
sulfate and concentrated in vacuo. The final purification was effected by silica-gel column
chromatography (EtOAc:MeOH, 75:25) to afford 14 (2.49 g, 72%) as an oil. The spectral
data of 14 were found to be comparable with a genuine sample prepared previously [21].
2.3. Binding assay
The affinities of bisphosphate analogues for the human P2Y1 receptor were directly
determined by using [3H]MRS2279 in a radioligand binding assay, as we recently described
in detail [18]. Briefly, the human P2Y1 receptor was expressed in 1321N1 astrocytoma cells.
Membranes prepared from these cells were incubated for 30 min at 4 °C in the presence of
~20 nM [3H]MRS2279 and a wide range of concentrations of the nucleotide analogues.
Binding reactions were terminated by the addition of ice-cold
tris(hydroxymethyl)aminomethane (Tris) wash buffer (10 mM Tris, pH 7.5, and 145 mM
NaCl) to the samples followed by rapid filtration over GF/A glass-fiber filters. Each filter
was washed with an additional 4 mL of wash buffer, and radioactivity retained by the filters
was quantified by liquid scintillation spectrometry. All assays were carried out in triplicate,
and competition curves for all molecules were generated in three separate experiments. IC50
values were determined from each competition curve, and a Ki value was calculated for each
analogue according to the relationship Ki = IC50/1 + [[3H]MRS2279]/Kd of [3H]MRS2279,
where the Kd of [3H]MRS2279 determined in separate experiments was 8 nM.
2.4. Preparation of washed platelet suspensions
Six volumes of blood were drawn into one volume of acid-citrate-dextrose anticoagulant.
Twice washed platelet suspensions were prepared according to the method described by
Mustard et al. [25], with the exception that 500 nmol/L PGI2 was added during the first and
second wash. The number of platelets was adjusted to 4 × 1011/L in the final suspension,
which contained Tyrode’s buffer, 0.35% bovine serum albumin, 0.1% dextrose and 1 μL/
mL apyrase.
2.5. Studies of platelet aggregation and shape change
The inhibition of ADP-induced activation of human platelets was measured using
aggregometry using washed platelet suspensions. Samples of washed platelet suspensions
(0.45 mL) were incubated with vehicle or test compounds at 37 °C for 30 s and stirred at
1000 rpm in an aggregometer (Lumi-Aggregometer, Chrono-log Corp.). After incubation,
10 μL of ADP (final concentration, 5 μmol/L) was added and the aggregation tracings were
recorded for 3 min. The initial rapid decrease in oscillations of the basal tracings and
increase in optical density were interpreted as being caused by a platelet shape change.
Concentration response curves for antagonists were constructed, and the IC50 values
determined (n = 3).
2.6. Measurement of intracellular ionized calcium ([Ca2+]i)in platelets
Platelets were loaded with 2 μmol/L fura-2/AM at 37 °C for 45 min as previously described
[26]. Aliquots of fura-2/AM-loaded platelets were transferred to quartz cuvettes maintained
at 37 °C. Fluorescence was monitored continuously before and after stimulation with ADP,
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using a spectrofluorimeter (LS50B, Perkin-Elmer Co.). The excitation wavelength was
alternatively fixed at 340 and 380 nm, and fluorescence emission was determined at 510 nm.
2.7. Measurement of cyclic AMP (cAMP) in platelets
Platelet cyclic AMP levels were measured by a radioisotopic assay, using a commercially
available kit (Amersham). Duplicate samples of 1 mL washed platelets containing
theophylline (1 mM) were incubated with: (a) Tyrode’s buffer and PGE1 (1 μmol/L), (b)
Tyrode’s buffer, PGE1 and ADP (10 μM) or (c) Tyrode’s buffer alone. After incubation at
37 °C (2 min), 1 mL of 5% trichloroacetic acid was added, and the samples were snap-
frozen in dry ice and methanol, thawed at room temperature (22–25 °C), and then shaken at
4 °C for 45 min. After centrifugation at 4 °C for 30 min, the supernatant was extracted three
times with 5 mL of water-saturated ether, dried under a stream of nitrogen at 60 °C, and
stored at −20 °C. Before assay, the samples were reconstituted with 50 mM Tris buffer
containing 4 mM EDTA.
2.8. Statistical analysis
Pharmacological parameters were analyzed by Graph-PAD Prism software. Data were
expressed as mean ± standard error.
3. Results
3.1. Chemistry
An improved synthetic method for the preparation of MRS2500 4 is shown in Fig. 2. The
previous route of Kim et al. [19] featured a condensation of the N6-methyl-2-iodoadenine
with the prephosphorylated and protected (N)-methanocarba ring system 10. In contrast, the
present method began with the Mitsunobu coupling of 6-chloro-2-iodoadenine with the same
methanocarba ring moiety 10 to provide 11. Following deprotection of the phosphate esters
of 11 to yield 12, the 6-chloro was substituted with methylamine resulting in MRS2500 4.
This synthetic route also would be amenable to tritium labeling upon treatment of 12 with
labeled methylamine, similar to the route used for labeling MRS2279 [18].
We devised an alternate approach to the synthesis of intermediate 10. The previous study
used a 1′-acetoxy protection scheme in the phosphorylation step. The present method used
the orthogonal protection scheme of transient acetylation of the 3′-and 5′-hydroxyl groups
7, followed by silylation of the 1′-hydroxyl and removal of the esters using potassium
carbonate, to provide intermediate 8. Phosphorylation was carried out using the
phosphoramidite method as described [19], and subsequent desilylation provided 10 in high
yield.
The acyclic phosphonate MRS2496 was prepared by the method reported by Xu et al. [23],
except that an improvement was made in the preparation of the intermediate tetraethyl 2-
hydroxymethyl-1,3- propane bisphosphonate 14 from diethyl 2-(diethylphosphonomethyl)-
allylphosphonate 13. Use of borane-tetrahydrofuran complex in this hydroboration step
proved superior to 9-borabicyclo[3.3.1]nonane (9-BBN) in giving higher yields as well as a
simpler product isolation procedure.
3.2. Inhibition of radioligand binding at the human P2Y1 receptor
The affinity of the three nucleotide bisphosphate analogues at the human P2Y1 receptor
expressed in 1321N1 astrocytoma cells was determined in a binding assay using the recently
introduced antagonist radioligand [3H]MRS2279 [18] and Ki values were calclulated (Table
1). The order of affinity based on Ki values was 4 ≫ 5 > 6. Thus, the conformationally
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constrained analogue 4 was demonstrated to have extremely high receptor affinity, while the
two acyclic compounds were of intermediate affinity.
3.3. Inhibition of ADP-induced platelet responses
Three nucleotide bisphosphate analogues were examined as inhibitors of ADP-induced
aggregation of human platelets, using platelet aggregometry [23,26]. Compound 4, the (N)-
methanocarba derivative, was highly potent in inhibiting ADP (10 μM)-induced platelet
aggregation with an IC50 value of 0.95 nM. Compound 5, the acyclic bisphosphate
antagonist MRS2298, and compound 6, the bisphosphonate acyclic nucleotide, also
inhibited ADP (10 μM)-induced platelet aggregation in a concentration-dependent manner
(Table 1) and with IC50 values of 62.8 nM and 1.5 μM, respectively. The effect of these
three P2Y1 receptor antagonists in ADP-promoted Ca2+ mobilization also was examined in
human platelets. All three antagonists inhibited ADP (10 μM)-induced increases in intra-
cellular calcium, and the order of potency for inhibition (4 > 5 > 6) was the same as
observed for inhibition of ADP-promoted aggregation (Table 1).
All three antagonists also inhibited ADP-promoted shape change with an order of potency
identical to that observed for aggregation and Ca2+ responses. In contrast to platelet
aggregation, the inhibition of ADP (10 μM)-induced platelet shape change was complete at
concentrations of the compounds that completely inhibited the ADP-induced intracellular
Ca2+ rise (Fig. 3).
The cAMP inhibitory pathway in platelets [26] is associated with activation of P2Y12
receptors. We examined whether any of these three antagonists for interaction with the
P2Y12 receptor-promoted pathway (Table 1 and Fig. 3). No significant effect of compound 4
was observed on the capacity of 10 μM ADP to inhibit PGE1-stimulated cAMP
accumulation. Compounds 4 and 6 at the highest concentration tested (1 mM) caused
approximately 40% inhibition of the ADP (10 μM)-induced effects on cAMP. Compounds
4, 5, and 6 alone had no effect on basal cAMP levels (not shown).
4. Discussion
We have compared the effects of three antagonists of the P2Y1 receptor on ADP-induced
responses in human platelets and at recombinant human P2Y1 receptors. All compounds
exhibited selective and potent antagonism of the P2Y1-dependent responses of platelets to
ADP. The potency order was consistently 4 > 5 > 6 by a variety of criteria for antagonism of
P2Y1 receptors (Table 1). The same order of potency was observed for all three antagonists
for the inhibition of ADP-promoted Ca2+ mobilization, shape change, and aggregation.
Lower concentrations of antagonists were necessary to inhibit completely platelet
aggregation than shape change and Ca2+ mobilization, apparently because platelet
aggregation requires a higher degree of receptor occupancy by ADP than shape change and
Ca2+ mobilization [27]. In a previous study [23] it was demonstrated the 5 and 6 inhibited
the aggregation of rat platetets induced by 3.3 μM ADP in platelet-rich plasma with IC50
values of 300 and 680 nM, respectively. Compound 4 was reported to inhibit the activation
of PLC induced by 30 nM 2-methylthio-ADP with an IC50 value of 8.4 nM [19]. Thus, the
order of potency is consistent with previous findings.
Each of the three compounds has a unique chemical character. The most potent antagonist,
MRS2500, contains a novel rigid ring system, which has been shown to enhance P2Y1
receptor selectivity and impede the hydrolysis of pendant 5-phosphate esters [2]. MRS2298,
the flexible, yet structurally optimized acyclic phosphate ester [22], was intermediate in
potency. Finally, a bisphosphonate MRS2496 [23], structurally similar to MRS2298, except
more chemically and biologically stable due to the present of C-P bonds rather than C-O-P
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bonds, also inhibited P2Y1-receptor mediated platelet function at micromolar
concentrations.
No substantial antagonism of the pathway linked to the inhibition of cyclic AMP was
observed with these three P2Y1 receptor antagonists, indicating no interaction with the
proaggregatory P2Y12 receptor, which is also activated by ADP. Thus, we have
demonstrated the functional selectivity of the derivatives for the P2Y1 receptor in human
platelets. It will be important to examine the activity of these compounds in isolated organs
and in vivo. This would further clarify the feasibility of using P2Y1 receptor antagonists as
antithrombotic agents, which has already been established experimentally. A previously
reported P2Y1 receptor antagonist, the riboside derivative MRS2179, was studied in the
isolated guinea pig heart [28], to demonstrate that vasodilation induced by endogenous ADP
occurs principally through the P2Y1 receptor rather than the adenosine A2A receptor (as a
result of the breakdown of ADP to adenosine). These compounds will also be useful in
determining the relative importance of the two metabotropic ADP receptors in platelet
activation in vivo [29]. Since there are other known sites of the P2Y1 receptor in adult and
developing mammals [30], both in the brain and in the periphery (i.e. endothelial cells, bone
cells, skeletal muscle), it would be important to assess possible side effects of such proposed
therapeutic use using potent and relatively stable analogues. In summary, these selective
antagonists potentially are valuable as pharmacological tools for defining the role of P2Y1
receptors in platelet function and in other physiological processes.
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Structures of nucleotide (bisphosphate) derivatives that have been shown to act as inhibitors
of P2Y1 receptors. The nucleotide analogues differ mainly in the nature of the ribose-like
moiety and include 9-ribosides (1, 2), the (N)-methanocarba ring system, which is sterically-
constrained in the North 2′-exo conformation favored by the P2Y1 receptor (3, 4), and
acyclic analogues (5, 6).
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Improved synthetic routes for the preparation of the (N)-methanocarba antagonist MRS2500
4 and the acyclic antagonist MRS2496 6. The route applied to MRS2500 involves
phosphorylation of the [3.1.0]bicyclohexane system in 8, condensation with the nucleobase
using a Mitsunobu coupling to yield 11, followed by deprotection of the phosphate groups
and functional group replacement on the adenine moiety. The single step applied to the
preparation of MRS2500 involves hydroboration to form the intermediate 14.
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Concentration-response curve for inhibition of ADP-induced processes in human platelets
by MRS2500 4 (upper panel), the acyclic bisphosphate derivative 5 (middle panel), and the
acyclic bisphosphonate derivative 6 (lower panel). Aggregation was induced in the presence
of 10 μM ADP. The antagonism of the following parameters is expressed as percent (mean
± S.D.) of ADP-induced control in the presence of 1% DMSO: aggregation, increase in
Ca2+, and the inhibition of adenylate cyclase. An upper bar indicates whether the initial
shape change in the platelets was observed at each concentration of the antagonist.
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Table 1
Activities of the adenine nucleotide derivatives as antagonists of functions induced by 10 μM ADP in human
platelets and in a competitive binding assay at heterologously expressed human P2Y1 receptors in 1321
astrocytoma cells (n = 3)
IC50 or Ki (nM) (mean ± S.E.M.)




Inhibition of Ca2+ rise in
plateletsb IC50
Inhibition of cAMP
effects in plateletsb (IC50)
4 MRS2500 0.78 ± 0.08 0.95 ± 0.16 49.1 ± 6.7 >100,000
5 MRS2298 29.6 ± 3.3 62.8 ± 15.6 810 ± 207 >100,000
6 MRS2496 76 ± 10 1500 ± 250 16,100 ± 4600 >100,000
a
Using [3H]MRS2279 as radioligand [18].
b
In washed platelet suspensions.
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